NCT06997497
A Clinical Study of Calderasib (MK-1084) With Targeted Therapy and Chemotherapy in People With Colorectal Cancer (MK-1084-012/KANDLELIT-012)
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
The 50 most recent of 53 versions: 49 with changes below, 1 re-verified with no change. See every version on ClinicalTrials.gov ↗
- Minor Trial sites expanded: 243 → 247 locations
- Minor Study sites: 244 to 245
- Minor Study sites: 243 to 244
- Minor Trial sites expanded: 239 → 243 locations
- Minor Study sites: 238 to 239
Show 3 earlier versionsHide 3 earlier versions
- Notable Eligibility criteria expanded, about 17 words
- Study sites: 236 to 238
- Interventions: 5-Fluorouracil (Drug), Bevacizumab (Drug), Bevacizumab biosimilar (Drug), Calderasib (Drug), Cetuximab (Biological)… to 5-Fluorouracil (Drug), Bevacizumab (Drug), Bevacizumab biosimilar (Drug), Calderasib (Drug), Cetuximab (Biological)…
- Secondary endpoints: details revised at 14 of 15 entries
- Minor Study sites: 234 to 236v47
- Minor Study sites: 232 to 234v46
- Minor Trial sites expanded: 228 → 232 locationsv45
- Minor Trial sites expanded: 133 → 228 locationsv44
- Minor Trial sites reduced: 223 → 133 locationsv43
- Minor Trial sites expanded: 220 → 223 locationsv42
- Minor Trial sites expanded: 217 → 220 locationsv41
- Minor Study sites: 215 to 217v40
- Minor Trial sites expanded: 211 → 215 locationsv39
- Minor Trial sites expanded: 200 → 211 locationsv38
- Minor Trial sites expanded: 196 → 200 locationsv37
- Minor Trial sites expanded: 192 → 196 locationsv36
- Minor Trial sites expanded: 187 → 192 locationsv35
- Minor Trial sites expanded: 180 → 187 locationsv34
- Notable Eligibility criteria expanded, about 31 words
- Trial sites expanded: 161 → 180 locations
- Minor Trial sites expanded: 152 → 161 locationsv32
- Minor Trial sites expanded: 148 → 152 locationsv31
- Minor Trial sites expanded: 143 → 148 locationsv30
- Minor Trial sites expanded: 137 → 143 locationsv29
- Minor Trial sites expanded: 133 → 137 locationsv28
- Minor Study sites: 124 to 133v27
- Minor Study sites: 115 to 124v26
- Minor Study sites: 103 to 115v25
- Minor Study sites: 100 to 103v24
- Minor Study sites: 83 to 100v23
- Minor Study sites: 78 to 83v22
- Minor Interventions: 5-Fluorouracil (Drug), Bevacizumab (Drug), Bevacizumab biosimilar (Drug), Cetuximab (Biological), Leucovorin/levofolinate calcium (Drug)… to 5-Fluorouracil (Drug), Bevacizumab (Drug), Bevacizumab biosimilar (Drug), Calderasib (Drug), Cetuximab (Biological)…
- Study title expanded, about 1 word
- Minor Study sites: 74 to 78v20
- Minor Study sites: 71 to 74v19
- Minor Study sites: 69 to 71v18
- Minor Study sites: 68 to 69v17
- Minor Primary completion date: Aug 27, 2029 to Mar 28, 2029
- Interventions: 5-Fluorouracil (Drug), Bevacizumab (Drug), Cetuximab (Biological), Leucovorin/levofolinate calcium (Drug), MK-1084 (Drug), Oxaliplatin… to 5-Fluorouracil (Drug), Bevacizumab (Drug), Bevacizumab biosimilar (Drug), Cetuximab (Biological), Leucovorin/levofolinate calcium (Drug)…
- Secondary endpoints: details revised at 12 of 15 entries
- Minor Study sites: 65 to 68v15
- Minor Study sites: 62 to 65v14
- Minor Study sites: 59 to 62v13
- Minor Study sites: 52 to 59v12
- Minor Study sites: 43 to 52v11
- Minor Study sites: 30 to 43v10
- Minor Study sites: 23 to 30v9
- Minor Study sites: 19 to 23v8
- Minor Study sites: 18 to 19v7
- Minor Study sites: 8 to 18v6
- Minor Study sites: 3 to 8v5
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Secondary (15)
Show 10 moreShow less
Arms and interventions
Participants will receive calderasib orally, cetuximab per label every 2 weeks (Q2W), and mFOLFOX6 chemotherapy: oxaliplatin per label every 2 weeks (Q2W), leucovorin or levofolinate calcium per label Q2W, and 5-fluorouracil (5-FU) per label Q2W. Treatment will continue until criteria for discontinuation is met.
Participants will receive mFOLFOX6 chemotherapy: oxaliplatin per label Q2W, leucovorin or levofolinate calcium per label Q2W, and 5-fluorouracil (5-FU) per label Q2W. Participants may also receive bevacizumab or bevacizumab biosimilar Q2W at the investigator's discretion. Treatment will continue until criteria for discontinuation is met.
Drugs: Calderasib, Oxaliplatin, Leucovorin/levofolinate calcium, 5-Fluorouracil, Bevacizumab, Bevacizumab biosimilar
Biologicals: Cetuximab
Sites
247 sites in 29 countries
United States 50, China 36, Japan 16, Ukraine 12, France 11, Brazil 10, Chile 10, Spain 9, Italy 8, South Korea 8, Argentina 6, Canada 6, Mexico 6, Turkey (Türkiye) 6, United Kingdom 6, Israel 5, Poland 5, Romania 5, Australia 4, Germany 4, Netherlands 4, Taiwan 4, Colombia 3, Malaysia 3, Philippines 3, Finland 2, Hong Kong 2, Hungary 2, Singapore 1